Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion (+2% vs 2022), across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| BAX | BAXTER INTERNATIONAL INC | 2026-02-17 19:25:07 | 20.67 | -0.07 | -0.33 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BAX | 0000010456 | BAXTER INTERNATIONAL INC | US0718131099 | J5OIVXX3P24RJRW5CK77 | 360781620 | NYSE | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | ONE BAXTER PARKWAY | DEERFIELD | IL | 60015 | UNITED STATES | US | 2249482000 | ONE BAXTER PARKWAY, DEERFIELD, IL, 60015 | ONE BAXTER PARKWAY, DEERFIELD, IL, 60015 | — | Medical equipment | 1931 | Andrew Hider | 38,000 | http://baxter.com | 17,000,000,000 | 683,494,944 | 514,055,805 | Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion (+2% vs 2022), across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals. | 2026-02-12 16:05:25 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 16,000,000,000 | -1,000,000,000 | -5.8824 | 514,490,045 | 2,865,049 | 0.56 |
| 2024 | 17,000,000,000 | -6,000,000,000 | -26.087 | 511,624,996 | 3,797,559 | 0.7478 |
| 2023 | 23,000,000,000 | -9,000,000,000 | -28.125 | 507,827,437 | 3,155,271 | 0.6252 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Heather Knight | Chief Operating Officer, Executive Vice President, Group President | 2024 | 883,333 | 0 | 4,607,152 | 1,039,500 | 66,505 | 6,596,490 |
| Alok Sonig | Executive Vice President, Group President | 2024 | 787,500 | 0 | 3,583,345 | 904,000 | 70,961 | 5,345,806 |
| José E. Almeida | Chair, Chief Executive Officer, President | 2024 | 1,300,000 | 0 | 14,319,107 | 2,016,300 | 435,608 | 18,071,015 |
| Joel Grade | Chief Financial Officer, Executive Vice President | 2024 | 810,000 | 500,000 | 4,295,702 | 839,608 | 62,238 | 6,507,548 |
| Christopher Toth | Executive Vice President, Group President | 2024 | 1,000,000 | 0 | 5,119,077 | 1,387,500 | 78,224 | 7,584,801 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 37,500 |
| 2024 | 38,000 |
| 2023 | 60,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 11,244,000,000 | 10,636,000,000 | 14,813,000,000 |
| Cost Of Revenue | 7,865,000,000 | 6,652,000,000 | 9,838,000,000 |
| Gross Profit | 3,379,000,000 | 3,984,000,000 | 4,975,000,000 |
| Research And Development Expenses | 518,000,000 | 590,000,000 | 667,000,000 |
| General And Administrative Expenses | 2,890,000,000 | 2,967,000,000 | 3,946,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | -308,000,000 | 14,000,000 | 390,000,000 |
| Net Income | -957,000,000 | -649,000,000 | 2,656,000,000 |
| Earnings Per Share Basic | -1.87 | -1.27 | 5.25 |
| Earnings Per Share Diluted | -1.87 | -1.27 | 5.25 |
| Weighted Average Shares Outstanding Basic | 513,000,000 | 510,000,000 | 506,000,000 |
| Weighted Average Shares Outstanding Diluted | 513,000,000 | 510,000,000 | 506,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,966,000,000 | 1,764,000,000 | 3,194,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 1,700,000,000 | 1,540,000,000 | 2,430,000,000 |
| Inventories | 2,232,000,000 | 2,046,000,000 | 2,824,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 341,000,000 | 205,000,000 | 387,000,000 |
| Total Assets Current | 6,872,000,000 | 8,853,000,000 | 9,600,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 2,910,000,000 | 2,870,000,000 | 4,433,000,000 |
| Other Assets Non Current | 699,000,000 | 755,000,000 | 1,126,000,000 |
| Total Assets Non Current | 13,183,000,000 | 16,929,000,000 | 18,676,000,000 |
| Total Assets | 20,055,000,000 | 25,782,000,000 | 28,276,000,000 |
| Accounts Payable | 999,000,000 | 968,000,000 | 1,241,000,000 |
| Deferred Revenue | 141,000,000 | 131,000,000 | 148,000,000 |
| Short Term Debt | 1,000,000 | 2,126,000,000 | 0 |
| Other Liabilities Current | 1,968,000,000 | 1,861,000,000 | 2,594,000,000 |
| Total Liabilities Current | 2,970,000,000 | 6,511,000,000 | 6,503,000,000 |
| Long Term Debt | 9,438,000,000 | 13,180,000,000 | 13,855,000,000 |
| Other Liabilities Non Current | 1,287,000,000 | 1,076,000,000 | 1,737,000,000 |
| Total Liabilities Non Current | 10,983,000,000 | 12,247,000,000 | 13,305,000,000 |
| Total Liabilities | 13,953,000,000 | 18,758,000,000 | 19,808,000,000 |
| Common Stock | 683,000,000 | 683,000,000 | 683,000,000 |
| Retained Earnings | 13,705,000,000 | 14,929,000,000 | 16,114,000,000 |
| Accumulated Other Comprehensive Income | -3,754,000,000 | -4,010,000,000 | -3,554,000,000 |
| Total Shareholders Equity | 6,129,000,000 | 6,964,000,000 | 8,402,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 981,000,000 | 997,000,000 | 1,263,000,000 |
| Share Based Compensation Expense | 117,000,000 | 114,000,000 | 133,000,000 |
| Other Non Cash Income Expense | -30,000,000 | -41,000,000 | -77,000,000 |
| Change In Accounts Receivable | 132,000,000 | 35,000,000 | 66,000,000 |
| Change In Inventories | 119,000,000 | 201,000,000 | 114,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 3,000,000 | 112,000,000 | 107,000,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 845,000,000 | 1,019,000,000 | 1,726,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | 0 | 34,000,000 | — |
| Acquisition Of Property Plant And Equipment | 513,000,000 | 446,000,000 | 692,000,000 |
| Acquisition Of Business | 9,000,000 | 14,000,000 | 6,000,000 |
| Other Investing Activities | -58,000,000 | -16,000,000 | -26,000,000 |
| Cash From Investing Activities | 2,841,000,000 | -626,000,000 | 3,213,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 267,000,000 | 536,000,000 | 592,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | 0 | 0 |
| Issuance Of Long Term Debt | 1,998,000,000 | — | 0 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -57,000,000 | -31,000,000 | -65,000,000 |
| Cash From Financing Activities | -4,216,000,000 | -1,081,000,000 | -3,489,000,000 |
| Change In Cash | -446,000,000 | -784,000,000 | 1,476,000,000 |
| Cash At End Of Period | 1,966,000,000 | 1,764,000,000 | 3,194,000,000 |
| Income Taxes Paid | 222,000,000 | 223,000,000 | 262,000,000 |
| Interest Paid | 303,000,000 | 401,000,000 | 484,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.87 | -1.27 | 5.25 |
| Price To Earnings Ratio | -10.2193 | -22.9606 | 7.3638 |
| Earnings Growth Rate | 47.2441 | -124.1905 | -208.6957 |
| Price Earnings To Growth Ratio | -0.2163 | 0.1849 | -0.0353 |
| Book Value Per Share | 11.8947 | 13.7725 | 16.7352 |
| Price To Book Ratio | 1.6066 | 2.1173 | 2.3101 |
| Ebitda | 536,000,000 | 979,000,000 | 4,693,000,000 |
| Enterprise Value | 17,276,430,000 | 28,413,600,000 | 30,222,960,000 |
| Dividend Yield | 0.0272 | 0.036 | 0.0303 |
| Dividend Payout Ratio | -0.279 | -0.8259 | 0.2229 |
| Debt To Equity Ratio | 1.5401 | 2.1979 | 1.649 |
| Capital Expenditures | 1,021,000,000 | -566,000,000 | 717,000,000 |
| Free Cash Flow | -176,000,000 | 1,585,000,000 | 1,009,000,000 |
| Return On Equity | -0.1561 | -0.0932 | 0.3161 |
| One Year Beta | 0.8697 | 0.462 | 0.6565 |
| Three Year Beta | 0.7234 | 0.5773 | 0.5606 |
| Five Year Beta | 0.6272 | 0.6475 | 0.6792 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Grade Joel T. | EVP and CFO | 2026-02-09 | 30,504 | A | 246,048 |
| Grade Joel T. | EVP and CFO | 2026-02-09 | 9,144 | D | 236,904 |
| Rasul Reazur | EVP,Group Pres,Healthcare | 2026-02-09 | 18,951 | A | 145,616 |
| Rasul Reazur | EVP,Group Pres,Healthcare | 2026-02-09 | 5,770 | D | 139,846 |
| Rosenbloom David S. | EVP and General Counsel | 2026-02-09 | 17,055 | A | 124,689 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel S Sullivan | Senator | 2023-07-26 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| Daniel S Sullivan | Senator | 2022-12-21 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| David A Perdue , Jr | Senator | 2021-05-02 | Sale (Full) | 2020-04-14 | Joint | $15,001 - $50,000 |
| David A Perdue , Jr | Senator | 2020-05-08 | Sale (Full) | 2020-04-14 | Joint | $15,001 - $50,000 |
| David A Perdue , Jr | Senator | 2018-07-05 | Sale (Partial) | 2017-02-13 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lisa McClain | 2025-11-21 | MI09 | Purchase | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-31 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-10-22 | MI09 | Purchase | 2025-09-25 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-09-12 | MI09 | Sale | 2025-08-04 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| HARRIS ASSOCIATES L P | 2025-12-31 | 161,399,841 | 8,445,832 | 19.11 |
| LAZARD ASSET MANAGEMENT LLC | 2025-12-31 | 118,252,890 | 6,188,011 | 19.11 |
| Cetera Investment Advisers | 2025-12-31 | 1,919,875 | 100,464 | 19.1101 |
| GUGGENHEIM CAPITAL LLC | 2025-12-31 | 914,872 | 47,874 | 19.11 |
| Scarborough Advisors, LLC | 2025-12-31 | 1,278 | 67 | 19.0746 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXUGX | 1,380,000 | 1,396,585.31 | 0.1006 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXLMX | 1,380,000 | 1,396,585.31 | 0.1006 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXKWX | 77,558 | 1,482,133.4 | 0.016 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXVIX | 77,558 | 1,482,133.4 | 0.016 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXCOX | 1,000,000 | 628,563.38 | 0.0131 |